Search

Coronavirus disease 2019 (COVID-19) vaccines have proven to be safe, effective and life-saving. However, little information is available on the neurological complications of COVID-19 vaccine. Here, we report a case who developed acute encephalomyelitis 1 week after being vaccinated with AstraZeneca COVID-19 vaccine (AZ vaccine). Autoimmune/inflammatory syndrome induced by adjuvants (ASIA) was also suspected. After intravenous dexamethasone and subcutaneous fondaparinux therapy, he returned to normal life without neurological sequelae. Four months later, he received Moderna COVID-19 vaccine without any sequelae.

Mechanisms underlying functional recovery after stroke are little known, and effective drug intervention during the delayed stage is desirable. One potential drug target, the protein-protein interaction between neuronal nitric oxide synthase (nNOS) and postsynaptic density protein 95 (PSD-95), is critical to acute ischaemic damage and neurogenesis. We show that nNOS-PSD-95 dissociation induced by microinjection of a recombinant fusion protein, Tat-nNOS-N1-133 , or systemic administration of a small-molecule, ZL006, from day 4 to day 10 after photothrombotic ischaemia in mice reduced excessive tonic inhibition in the peri-infarct cortex and ameliorated motor functional outcome. We also demonstrated improved neuroplasticity including increased dendrite spine density and synaptogenesis after reducing excessive tonic inhibition by nNOS-PSD-95 dissociation. Levels of gamma-aminobutyric acid (GABA) and GABA transporter-3/4 (GAT-3/4) are increased in the reactive astrocytes in the peri-infarct cortex. The GAT-3/4-selective antagonist SNAP-5114 reduced tonic inhibition and promoted function recovery, suggesting that increased tonic inhibition in the peri-infarct cortex was due to GABA release from reversed GAT-3/4 in reactive astrocytes. Treatments with Tat-nNOS-N1-133 or ZL006 after ischaemia inhibited astrocyte activation and GABA production, prevented the reversal of GAT-3/4, and consequently decreased excessive tonic inhibition and ameliorated functional outcome. The underlying molecular mechanisms were associated with epigenetic inhibition of glutamic acid decarboxylase 67 and monoamine oxidase B expression through reduced NO production. The nNOS-PSD-95 interaction is thus a potential target for functional restoration after stroke and ZL006, a small molecule inhibitor of this interaction, is a promising pharmacological lead compound. Copyright © 2017 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.

The synthesis and crystal structure of novel trinuclear molybdenum cluster compound with somewhat “loose” coordination site {Mo3(μ3-S)(μ-S)3[S2P(OEt)2l4 ṁ P(C6H5)3} ṁ (0.86 CH2C12) have been reported. The cluster crystallizes in the space group with two molecules in a unit cell whose parameters are a=10.472(4), b=14.375(2), c=21.695(3)A; α=74.04(1)°, β=76.50(2)°, γ=72.22 (2)°, V=2950A3 and Do=1.693 g ṁ cm−3. On the basis of 4840 independent reflections with I≥2σ(I), the structure was solved by heavy atom method and Fourier method and refined by full-matrix least-squares techniques to a final R=0.058. The distances between Mo atoms in this cluster are 2.731(1), 2.748(1) and 2.753(1)A respectively. The meat value of Mo—Mo bond lengths is slightly shorter than those in other trinuclear Mo clusters with “loosely coordinated” site. In addition, the PPh3 ligand is loosely coordinated to one Mo atom in direction opposite to the μ3-S with Mo—P bond length of 2.647(3)A. This is different from the other structurally analogous clusters, in which the loosely coordinated ligand is trans to μ2-S. A summary of Mo—Mo and Mo—L bonding for such clusters is given.